A
ADC Therapeutics SA (ADCT)
NYQ – Real Time Price. Currency in USD
3.43
-0.05 (-1.44%)
At close: May 12, 2026, 4:00 PM EDT
3.45
+0.02 (0.58%)
Pre-market: May 13, 2026, 4:37 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
3.43
-0.05 (-1.44%)
At close: May 12, 2026, 4:00 PM EDT
3.45
+0.02 (0.58%)
Pre-market: May 13, 2026, 4:37 AM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.09 | 6.05 | 10 | |
| Quick ratio | 4.02 | 5.63 | 10 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 0.40 | 1.04 | 6.0 | |
| Interest coverage | -2.04 | -16.91 | 1.0 | |
| Weighted average score | 5.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 210M | 70M | 71M | 81M | 79M |
| Gross Profit | 204M | 64M | 62M | 74M | 71M |
| Operating Income | -121M | -164M | -131M | -108M | -105M |
| Net Income | -157M | -240M | -158M | -143M | -137M |
| EBITDA | -119M | -161M | -127M | -107M | -104M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 3.91 | 58.67 | 7.0 |
| Next quarter | 16.75 | 27.78 | 9.5 |
| Current year | 0.04 | 24.26 | 6.0 |
| Next year | 68.2 | 27.15 | 10 |
| Weighted average score | 8.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -9.56 | -414.39 | -424.99 | 4.16 | 1.8 |
| Y/Y | -9.46 | 14.6 | 41.67 | 47.45 | 7.3 |
| 3y average | -16.71 | -2.95 | 9.34 | -1.12 | 2.3 |
| 5y average | 293.55 | 5.88 | 10.04 | -0.35 | 5.8 |
| Weighted average score | 4.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $231.0M significantly exceed its total debt $116.7M, ensuring strong financial flexibility
Total current assets $276.8M exceed Total current liabilities $67.6M, highlighting excellent liquidity
Debt-to-equity ratio (-0.5) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-2.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$29.7M limits the company's ability to reinvest or pay down debt